Neuroendocrine differentiation is a term pathologists use to describe cells that exhibit features of both nerve cells and hormone-producing cells. These cells are capable of producing, storing, and releasing hormones, much like cells in the nervous and endocrine systems.
Neuroendocrine differentiation can be seen in both normal tissues and tumours. When seen in a tumour, it means that some or all of the tumour cells behave like neuroendocrine cells. These tumours can be benign (non-cancerous) or malignant (cancerous).
This feature is important because it can help doctors better understand the type of tumour and choose the most appropriate treatment. In some cases, neuroendocrine differentiation may be found in tumors that are not typically composed of neuroendocrine cells, such as certain types of prostate or lung cancer. When this happens, it may affect how the tumour behaves and how it responds to treatment.
For pathologists, recognizing neuroendocrine differentiation in a tumour provides important information that can help guide diagnosis, treatment, and prognosis.
Diagnosis – Neuroendocrine differentiation helps identify the exact type of cancer. Some cancers are entirely composed of neuroendocrine cells, while others may exhibit only partial neuroendocrine features. This information can help distinguish neuroendocrine tumours from other types of cancer.
Prognosis – The presence of neuroendocrine differentiation can affect how the tumour behaves. Tumours with this feature may grow faster, be more aggressive, or respond differently to treatment. In some cases, it may indicate a higher risk of the cancer spreading.
Treatment planning – Some treatments are specifically designed for tumours with neuroendocrine features. Knowing that a tumour shows neuroendocrine differentiation can help doctors choose the most appropriate therapies, including chemotherapy or targeted treatments that work best for these types of cells.
Pathologists use two primary methods to identify neuroendocrine differentiation: microscopic examination and immunohistochemistry.
Microscopic examination – Pathologists first look at the tissue sample under a microscope. Tumours with neuroendocrine differentiation often have cells with round nuclei and a unique pattern of chromatin (genetic material) that looks finely speckled. This pattern is often described as “salt and pepper” chromatin. The tumour cells may also grow in specific patterns, such as nests, rosettes, or sheets.
Immunohistochemistry (IHC) – This specialized laboratory test utilises antibodies to detect specific proteins produced by neuroendocrine cells. The most commonly used markers for neuroendocrine differentiation are synaptophysin, chromogranin, and CD56.
If the tumour cells produce one or more of these proteins, it supports the diagnosis of neuroendocrine differentiation.
Neuroendocrine differentiation can be seen in a wide range of tumours. In some cases, the entire tumour is made up of neuroendocrine cells. In others, only a portion of the tumour shows this feature.
Neuroendocrine tumours (NETs) – These tumours are made entirely of neuroendocrine cells. They can develop in many parts of the body, most commonly in the gastrointestinal tract, pancreas, and lungs. NETs are often slow-growing but can still spread to other parts of the body.
Small cell lung cancer (SCLC) – This is an aggressive type of lung cancer that almost always shows neuroendocrine differentiation. It is usually a fast-growing condition that requires immediate treatment.
Prostate cancer – Some prostate cancers may show neuroendocrine differentiation, especially in advanced stages or after hormone therapy. These tumours may behave more aggressively and may require different treatment strategies.
Other cancers – In rare cases, tumours from different parts of the body, such as the breast, bladder, or cervix, may also show neuroendocrine differentiation. This feature can influence how the cancer is treated and its expected behaviour.
What does neuroendocrine differentiation mean in my diagnosis?
Is the entire tumour made of neuroendocrine cells, or just part of it?
How does this affect my treatment plan or prognosis?
Were special tests like immunohistochemistry used to confirm the diagnosis?
Are there specific treatments recommended for tumours with neuroendocrine differentiation?